The COL4A3 gene is located on chromosome 2 at q36.3 and encodes the protein collagen alpha-3(IV) chain. COL4A3 was first reported in relation to autosomal recessive Alport Syndrome in 1994 (Mochizuki et al., PMID: 7987396). Alport syndrome is characterized by hearing loss, anterior lenticonus, and glomerular basement membrane defects that may progress to end-stage kidney disease. Patients often present with hematuria and worsening proteinuria. Kidney biopsy may identify focal segmental glomerulosclerosis and thin glomerular basement membranes with abnormal ultrastructure. Autosomal dominant inheritance has also been reported, leading to an isolated renal phenotype of hematuria, with or without structural changes and progressive disease course. Case reports of digenic inheritance with COL4A4 or COL4A5 variants also exist. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism between the reported disease entities and noted that affected families show phenotypic variability with variable expressivity. Therefore, the following disease entities have been lumped into a single disease entity, Alport syndrome 3, autosomal dominant (OMIM:104200), Alport syndrome 2, autosomal recessive (OMIM:203780) and Hematuria, benign familial (OMIM:141200). The preferred disease name suggested for this grouping of disorders is ‘Alport Spectrum - COL4A3’. Twenty three variants (missense, nonsense, frameshift) that have been reported in 17 probands in 4 publications (PMID: 33532864, PMID: 33838161, PMID: 26346198, PMID: 7987396 ) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be loss-of-function. This gene-disease association is also supported by animal models (PMID: 32743880, PMID: 16775036, PMID: 33718859, PMID: 14507670), expression studies (PMID: 33718859, PMID: 28495876), and in vitro functional assays (PMID: 24262798, PMID: 14633121). In summary, COL4A3 is definitively associated with Alport Spectrum. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.